NCT01760291View on ClinicalTrials.gov

Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology

NACompletedINTERVENTIONAL
Enrollment

576

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Atrial Fibrillation
Interventions
DEVICE

WATCHMAN LAA Closure Technology

Trial Locations (3)

10029

Mount Sinai Medical Center, New York

40503

Central Baptist Hospital, Lexington

85006

Arizona Heart Rhythm Research Center, Phoenix

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY